Cargando…
Ototoxicity of cisplatinum in children and adolescents.
Twenty-two children and adolescents who had received cisplatinum for the treatment of solid tumours underwent audiometry to ascertain the extent of hearing damage. Five patients complained of hearing difficulties, causing difficulty at school in one child. Hearing loss greater than 20 decibels occur...
Autores principales: | Skinner, R., Pearson, A. D., Amineddine, H. A., Mathias, D. B., Craft, A. W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971678/ https://www.ncbi.nlm.nih.gov/pubmed/2372498 |
Ejemplares similares
-
Ototoxicity of cisplatinum.
por: Brock, P., et al.
Publicado: (1991) -
The Northern region Children's malignant disease registry 1968-82: incidence and survival.
por: Craft, A. W., et al.
Publicado: (1987) -
A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Publicado: (1990) -
The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia.
por: Pearson, A. D., et al.
Publicado: (1991) -
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
por: Hu, Guofang, et al.
Publicado: (2016)